open access

Vol 1, No 4 (2005)
Review paper
Published online: 2005-12-12
Get Citation

Monoclonal antibodies in the treatment of solid tumours

Katarzyna Sosińska-Mielcarek, Jacek Jassem
Onkol. Prak. Klin 2005;1(4):225-232.

open access

Vol 1, No 4 (2005)
REVIEW ARTICLES
Published online: 2005-12-12

Abstract

Monoclonal antibodies are a new class of anticancer agents, with different mechanism of action and toxicity compared to other systemic methods of treatment. Antibodies, by binding with selected receptors on tumour cell surface, block signal transduction and inhibit tumour proliferation. Monoclonal antibodies have been tested in cancer patients for many years, but only recently introduction of chimeric and humanized forms with limited side effects allowed using these compounds in large clinical trials. Until now US Food and Drug Administration (FDA) has registered eight anticancer monoclonal antibodies, including three for solid tumours. Those include trastuzumab, used in metastatic breast cancer, and cetuximab and bevacizumab, both used in advanced colon cancer. Ongoing clinical trials investigate new cancer indications for the use of monoclonal antibodies. Additionally, there is a continuous search for new monoclonal antibodies.

Abstract

Monoclonal antibodies are a new class of anticancer agents, with different mechanism of action and toxicity compared to other systemic methods of treatment. Antibodies, by binding with selected receptors on tumour cell surface, block signal transduction and inhibit tumour proliferation. Monoclonal antibodies have been tested in cancer patients for many years, but only recently introduction of chimeric and humanized forms with limited side effects allowed using these compounds in large clinical trials. Until now US Food and Drug Administration (FDA) has registered eight anticancer monoclonal antibodies, including three for solid tumours. Those include trastuzumab, used in metastatic breast cancer, and cetuximab and bevacizumab, both used in advanced colon cancer. Ongoing clinical trials investigate new cancer indications for the use of monoclonal antibodies. Additionally, there is a continuous search for new monoclonal antibodies.
Get Citation

Keywords

monoclonal antibodies; trastuzumab; bevacizumab; cetuximab; edrecolomab; targeted therapy

About this article
Title

Monoclonal antibodies in the treatment of solid tumours

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 4 (2005)

Article type

Review paper

Pages

225-232

Published online

2005-12-12

Bibliographic record

Onkol. Prak. Klin 2005;1(4):225-232.

Keywords

monoclonal antibodies
trastuzumab
bevacizumab
cetuximab
edrecolomab
targeted therapy

Authors

Katarzyna Sosińska-Mielcarek
Jacek Jassem

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl